MarketCapExport financials
Interpace Biosciences (IDXG)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Interpace Biosciences Income Statement 2025-2009 | IDXG
Brief overview of financial results at Interpace Biosciences
The overview follows changes across a five-year period. Revenue reported by Interpace Biosciences was $32.4 million at the beginning of the period and $38.7 million at the end. The total change was +19.5%, with a CAGR of approximately 3.6%. Revenue was effectively stagnant over the period.
The gross result shifted from $10.7 million to $24.1 million, or +125%. Direct costs grew more slowly than revenue and improved the economics of sales. Comparing the endpoints gives gross margins of 33.1% and 62.3%. Improving gross profitability strengthens the quality of revenue growth.
EBITDA changed from −22.1 million dollars to 4.5 million dollars (+120.4%). The operating result outpaced sales and points to improving efficiency. At the operating-margin level, the figure shifted from −68.2% to 11.6%. The business generated more EBITDA from each unit of revenue.
The net financial result changed from −$26.5 million to $24.6 million. The company restored profitability by the end of the period.
Market value was $16.2 million at the start and $7.3 million at the end. Investors remain cautious despite better financial results.
Conclusion
The results present an uneven picture without one dominant signal. The positive side is supported by positive operating leverage, a stronger gross margin and net-income growth. The overall view is constrained by limited revenue growth and a weaker market valuation. Further direction will depend on top-line growth, operating profitability, and net income.
Annual Income Statement Interpace Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
7.34 M | 4.12 M | 5.96 M | 4.66 M | 22.3 M | 16.2 M | 28.6 M | 25.3 M | 17.3 M | 7.55 M | 4.18 M | 23.2 M | 86.5 M | 112 M | 95.7 M | - | - |
Shares |
4.42 M | 4.39 M | 4.32 M | 4.24 M | 4.14 M | 4.03 M | 3.75 M | 2.82 M | 1.58 M | 182 K | 155 K | 149 K | 147 K | 146 K | 144 K | 14.3 M | - |
Historical Prices |
1.66 | 0.94 | 1.38 | 1.1 | 5.39 | 4.02 | 7.91 | 9.2 | 10.8 | 41.7 | 27 | 156 | 579 | 775 | 641 | - | - |
Net Income |
24.6 M | 6.7 M | 1.95 M | -22 M | -14.9 M | -26.5 M | -26.7 M | -12.2 M | -12.2 M | -8.33 M | -11.4 M | -16.1 M | -4.56 M | -25.5 M | -11.9 M | -6.81 M | - |
Revenue |
38.7 M | 46.9 M | 40 M | 5.68 M | 8.2 M | 32.4 M | 24.1 M | 21.9 M | 15.9 M | 13.1 M | 9.43 M | 120 M | 151 M | 127 M | 157 M | - | - |
Cost of Revenue |
14.6 M | 17 M | 15 M | 13.6 M | 14.3 M | 21.7 M | 15.9 M | 10.2 M | 7.36 M | 6.64 M | 6.91 M | 1.27 M | 17.4 M | 16.4 M | 19.7 M | 16.3 M | - |
Gross Profit |
24.1 M | 29.9 M | 25.1 M | 18.2 M | 18.8 M | 10.7 M | 8.19 M | 11.7 M | 8.54 M | 6.44 M | 2.52 M | 18.5 M | 24.4 M | 26.9 M | 32.5 M | 26.6 M | - |
Operating Income |
4.08 M | 8.11 M | 3.96 M | -3.62 M | -6.34 M | -26.1 M | -26.4 M | -12.6 M | -6.29 M | -6.44 M | -40.4 M | -17.8 M | -1.44 M | -25.2 M | -4.7 M | -6.9 M | - |
Interest Expense |
- | -394 K | -252 K | -1.21 M | -366 K | 549 K | 440 K | 331 K | 433 K | 14 K | -93 K | 602 K | - | -28 K | -14 K | 120 K | - |
EBITDA |
4.51 M | 8.41 M | 4.98 M | -1.06 M | -962 K | -22.1 M | -16 M | -4.09 M | -5.39 M | -7.4 M | -23.2 M | -9.84 M | -2.85 M | 1.02 M | -1.66 M | -5.07 M | - |
Operating Expenses |
20 M | 21.8 M | 21.1 M | 21.8 M | 25.1 M | 37.3 M | 28.4 M | 19 M | 17.2 M | 17.6 M | 29.6 M | 29.2 M | 28.7 M | 27.9 M | 37.2 M | 33.5 M | - |
General and Administrative Expenses |
9.48 M | 9.49 M | 9.36 M | 11 M | 10.7 M | 20.8 M | 14.5 M | 8.5 M | 9.15 M | 10.5 M | 16.9 M | 29.2 M | 28.7 M | 27.9 M | 34.3 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Interpace Biosciences
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
4.42 M | 22.8 M | - | 4.42 M | 4.42 M | 4.42 M | 4.41 M | 4.39 M | 4.38 M | 4.37 M | 4.35 M | 4.32 M | 4.31 M | 4.31 M | 4.3 M | 4.24 M | 4.23 M | 4.21 M | 4.2 M | 4.16 M | 4.1 M | 4.09 M | 4.06 M | 4.04 M | 4.03 M | 4 M | 3.92 M | 3.82 K | 3.81 M | 3.52 M | 2.87 M | 28.2 K | 27.9 M | 27.9 M | 27.8 M | 22 M | 9.66 M | 4.29 M | 2.18 M | 1.82 M | 1.82 M | 1.78 M | 1.77 M | 15.7 M | 15.2 M | 15 M | 15.4 M | 14.9 M | 14.9 M | 14.8 M | 15.2 M | 14.7 M | 14.7 M | 15 M | 15 M | 14.6 M | 14.6 M | 14.5 M | 14.7 M | 14.5 M | 14.4 M | 14.5 M |
Net Income |
1.65 M | 721 K | - | 911 K | -640 K | 1.65 M | - | 1.68 M | 2.44 M | 708 K | - | -614 K | 175 K | 351 K | - | -14.2 M | -3.94 M | -2.25 M | - | -3.56 M | -3.45 M | -4.21 M | -8.14 M | -6.23 M | -5.58 M | -6.49 M | -10.7 M | -7.45 M | -5.3 M | -3.33 M | -4.3 M | -3.13 M | -2 M | -3.28 M | - | -3.4 M | -6.39 M | 2.33 M | - | -8 M | -2.84 M | -5.3 M | - | -5.4 M | -7.49 M | -4.61 M | - | -4.45 M | -2.66 M | -1.61 M | - | -2.14 M | -883 K | 2.13 M | - | -1.02 M | -439 K | -272 K | - | -202 K | -895 K | -550 K |
Revenue |
9.23 M | 9.03 M | - | 8.76 M | 9.23 M | 11.5 M | - | 12.3 M | 12 M | 10.2 M | - | 9.08 M | 11 M | 9.83 M | - | 1.27 M | 1.96 M | 2.45 M | - | 8.06 M | 11.2 M | 9.83 M | - | 8.25 M | 5.45 M | 9.06 M | - | 7.72 M | 6.27 M | 6.01 M | - | 5.75 M | 5.5 M | 4.81 M | - | 4.2 M | 3.86 M | 3.47 M | - | 3.32 M | 3.61 M | 3.04 M | - | 2.51 M | 2.25 M | 2.12 M | - | 29.2 M | 31.6 M | 32.8 M | - | 34.3 M | 37.2 M | 42.9 M | - | 31.8 M | 27.8 M | 31.7 M | - | 36.1 M | 38.6 M | 44.3 M |
Cost of Revenue |
3.96 M | 3.13 M | - | 3.32 M | 3.96 M | 4.14 M | - | 4.39 M | 4.24 M | 3.87 M | - | 4.12 M | 4.19 M | 3.85 M | - | 3.46 M | 3.56 M | 3.26 M | - | 3.62 M | 5.8 M | 5.32 M | - | 5.19 M | 3.85 M | 6.11 M | - | 4.84 M | 3.03 M | 2.62 M | - | 2.76 M | 2.25 M | 2.58 M | - | 2.07 M | 1.88 M | 1.77 M | - | 1.85 M | 1.84 M | 1.18 M | - | 1.8 M | 1.85 M | 1.57 M | - | 24.4 M | 25.8 M | 26.7 M | - | 4.23 M | 4.91 M | 4.16 M | - | 4.08 M | 4.07 M | 4.58 M | - | 4.17 M | 5.7 M | 5.28 M |
Gross Profit |
5.28 M | 5.9 M | - | 5.44 M | 5.28 M | 7.37 M | - | 7.9 M | 7.81 M | 6.31 M | - | 4.95 M | 6.84 M | 5.98 M | - | 4.73 M | 3.83 M | 4.66 M | - | 4.44 M | 5.36 M | 4.52 M | - | 3.05 M | 1.6 M | 2.95 M | - | 2.89 M | 3.24 M | 3.39 M | - | 2.99 M | 3.25 M | 2.23 M | - | 2.13 M | 1.98 M | 1.7 M | - | 1.47 M | 1.77 M | 1.86 M | - | 707 K | 402 K | 543 K | - | 3.85 M | 5.19 M | 5.12 M | - | 4.7 M | 6.85 M | 8.47 M | - | 5.94 M | 6.57 M | 7.37 M | - | 7.68 M | 7.93 M | 8.16 M |
Operating Income |
-468 K | 1.12 M | - | 1.14 M | -468 K | 1.83 M | - | 2.3 M | 2.63 M | 1.11 M | - | -16 K | 832 K | 675 K | - | -780 K | -1.91 M | -977 K | - | -1.82 M | -2.91 M | -3.82 M | - | -6 M | -5.77 M | -6.35 M | - | -7.13 M | -5.35 M | -3.18 M | - | -2.46 M | -1.9 M | -3.25 M | - | -3.1 M | -3.6 M | 3.7 M | - | -6.49 M | -2.89 M | -3.8 M | - | -6.65 M | -7.71 M | -6.12 M | - | -3.2 M | -1.06 M | -414 K | - | -2.05 M | -847 K | 2.25 M | - | -756 K | -316 K | -221 K | - | 195 K | -1.07 M | -1.39 M |
Interest Expense |
-10 K | 10 K | - | -10 K | -10 K | - | - | 10 K | 14 K | -82 K | - | -252 K | -174 K | 19 K | - | -217 K | 37 K | 161 K | - | 49 K | -168 K | 135 K | - | 138 K | 167 K | 109 K | - | 111 K | 91 K | 129 K | - | 248 K | 33 K | 111 K | - | 40 K | -8 K | -36 K | - | 4 K | 3 K | 6 K | - | 969 K | 884 K | 848 K | - | - | - | - | - | 3 K | -24 K | -9 K | - | - | -15 K | -1 K | - | -48 K | -26 K | -65 K |
EBITDA |
-367 K | 1.24 M | - | 1.26 M | -367 K | 1.92 M | - | 2.39 M | 2.7 M | 1.17 M | - | 184 K | 1.13 M | 1.03 M | - | -480 K | -1.61 M | -196 K | - | 2.52 M | 37 K | -2.28 M | - | -1.9 M | -3.06 M | -5.03 M | - | -3.97 M | -3.43 M | -2.23 M | - | 115 K | -188 K | -2.39 M | - | -282 K | -1.66 M | 4.67 M | - | -3 M | -504 K | -2.54 M | - | -2.88 M | -5.21 M | -4.93 M | - | -1.87 M | -225 K | 43 K | - | -1.13 M | -270 K | 2.54 M | - | 734 K | 680 K | 280 K | - | 2.55 M | 493 K | -604 K |
Operating Expenses |
5.74 M | 4.78 M | - | 4.29 M | 5.74 M | 5.54 M | - | 5.6 M | 5.17 M | 5.2 M | - | 4.97 M | 6 M | 5.3 M | - | 5.51 M | 5.74 M | 5.64 M | - | 6.26 M | 8.26 M | 8.33 M | - | 9.06 M | 7.37 M | 9.3 M | - | 10 M | 8.59 M | 6.57 M | - | 5.46 M | 5.15 M | 5.48 M | - | 5.23 M | 5.57 M | -2 M | - | 7.96 M | 4.66 M | 5.66 M | - | 7.36 M | 8.12 M | 6.67 M | - | 7.06 M | 6.26 M | 5.53 M | - | 6.75 M | 7.7 M | 6.22 M | - | 6.7 M | 6.89 M | 7.59 M | - | 7.48 M | 9 M | 9.55 M |
General and Administrative Expenses |
2.66 M | 2.45 M | - | 2.06 M | 2.66 M | 2.55 M | - | 2.54 M | 2.14 M | 2.24 M | - | 2.12 M | 2.89 M | 2.49 M | - | 2.77 M | 2.98 M | 2.89 M | - | 2.57 M | 3.33 M | 2.98 M | - | 3.8 M | 3.98 M | 4.84 M | - | 4.49 M | 2.79 M | 2.74 M | - | 2.08 M | 1.73 M | 2.17 M | - | 2.12 M | 2.79 M | 1.52 M | - | 2.86 M | 2.02 M | 2.82 M | - | 2.5 M | 3.43 M | 3.34 M | - | 6.93 M | 6.26 M | 5.53 M | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Interpace Biosciences (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K |  USA |
 |
Biomerica
BMRA
|
$ 1.71 | -0.51 % | $ 4.98 M | USA |
 |
Myriad Genetics
MYGN
|
$ 5.57 | 0.54 % | $ 516 M | USA |
 |
Pacific Biosciences of California
PACB
|
$ 2.14 | 9.18 % | $ 642 M | USA |
 |
Neuronetics
STIM
|
$ 2.01 | 1.52 % | $ 133 M | USA |
 |
Agilent Technologies
A
|
$ 177.75 | 2.74 % | $ 50.5 B | USA |
 |
Charles River Laboratories International
CRL
|
$ 344.87 | 9.31 % | $ 17.1 B | USA |
 |
Biodesix
BDSX
|
$ 23.93 | 0.25 % | $ 181 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
$ 13.51 | 6.71 % | $ 142 M |  China |
 |
Bioventus
BVS
|
$ 14.24 | 2.08 % | $ 949 M | USA |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |
 |
CareDx, Inc
CDNA
|
$ 70.74 | 2.23 % | $ 3.77 B | USA |
 |
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | USA |
 |
Co-Diagnostics
CODX
|
$ 0.64 | -0.82 % | $ 851 K | USA |
 |
Danaher Corporation
DHR
|
$ 233.86 | 4.32 % | $ 167 B | USA |
 |
Fulgent Genetics
FLGT
|
$ 20.13 | -0.98 % | $ 620 M | USA |
 |
Surmodics
SRDX
|
- | - | $ 608 M | USA |
 |
IQVIA Holdings
IQV
|
$ 276.63 | 3.28 % | $ 47.6 B | USA |
 |
Invitae Corporation
NVTA
|
- | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
- | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K |  Israel |
 |
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M |  Britain |
 |
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | USA |
 |
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | USA |
 |
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | USA |
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
$ 323.75 | 0.19 % | $ 26.9 B | USA |
 |
Anixa Biosciences
ANIX
|
$ 2.71 | 1.12 % | $ 88 K | USA |
 |
Lantheus Holdings
LNTH
|
$ 100.24 | -0.15 % | $ 6.77 B | USA |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
Celcuity
CELC
|
$ 61.56 | 2.6 % | $ 2.88 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
Medpace Holdings
MEDP
|
$ 662.48 | 6.43 % | $ 19.1 B | USA |
 |
Mettler-Toledo International
MTD
|
$ 1 677.94 | 2.69 % | $ 34.6 B |  Schweiz |
 |
NeoGenomics
NEO
|
$ 17.04 | 2.53 % | $ 2.18 B | USA |
 |
Neogen Corporation
NEOG
|
$ 11.79 | 0.6 % | $ 2.56 B | USA |
 |
National Research Corporation
NRC
|
$ 20.31 | -1.84 % | $ 455 M | USA |
 |
Brainsway Ltd.
BWAY
|
$ 11.98 | -0.42 % | $ 407 M | Israel |
 |
Koninklijke Philips N.V.
PHG
|
$ 26.23 | 0.85 % | $ 24.9 B |  Niderland |
 |
Precipio
PRPO
|
$ 21.25 | -2.16 % | $ 34.1 M | USA |
 |
Castle Biosciences
CSTL
|
$ 34.37 | 3.68 % | $ 996 M | USA |
 |
Guardant Health
GH
|
$ 166.66 | 2.5 % | $ 20.9 B | USA |
 |
RadNet
RDNT
|
$ 68.41 | -1.78 % | $ 5.14 B | USA |
 |
DarioHealth Corp.
DRIO
|
$ 3.68 | -9.8 % | $ 14.7 M | Israel |
 |
DexCom
DXCM
|
$ 80.26 | -6.39 % | $ 31.3 B | USA |
 |
Senseonics Holdings
SENS
|
$ 7.97 | -2.92 % | $ 333 M | USA |
 |
Illumina
ILMN
|
$ 282.86 | 5.57 % | $ 43.8 B | USA |
 |
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M | Schweiz |